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The ISCHEMIA (In-
ternational Study of Com-
parative Health Effective-
ness with Medical and In-
vasive Approaches) trial 
[1] is a publicly funded 
clinical trial with a com-
plex design, elaboration, 
communication, and in-
terpretation of the results. 
There were 5179 patients 
randomized worldwide in 
the study. The results of the ISCHEMIA trial 
showed that patients with significant stable coro-
nary artery disease (CAD) that underwent invasive 
procedures, such as percutaneous coronary inter-
vention or coronary artery bypass graft surgery 
plus optimal medical treatment fared no better 
than patients who received only optimal medical 
therapy. The initial invasive strategy was associ-
ated with a reduction in angina and improved qual-
ity of life, only in symptomatic patients. 
The main finding was that, among stable 
patients who had evidence of moderate to severe 
ischemia on stress testing, an initial invasive 
strategy, when compared with an initial conserva-
tive strategy, was not associated with a reduction 
in the primary outcome of cardiovascular death, 
myocardial infarction (MI), hospitalization for un-
stable angina, hospitalization for heart failure, or 
resuscitated cardiac arrest over a median follow-up 
of 3.3 years. The primary composite endpoint oc-
curred in only 15.5% of patients in the conserva-
tive arm and 13.8% of patients in the invasive arm 
(p = 0.34); an observed event rate which was lower 
than predicted. Similar results were also observed 
for the pre-specified secondary endpoints of cardio-
vascular death or MI, and across the pre-specified 
sub-group analyses. 
For inclusion into the study, documentation 
of at least moderate ischemia on stress testing 
was required. Ischemia severity was based on 
a core-laboratory interpretation. The chosen stress 
tests were markedly variable: 50% nuclear myocar-
dial perfusion imaging via single-photon emission 
computed tomography or positron emission tomo-
graphy; 25% exercise treadmill testing (without im-
aging), 20% stress echocardiogram and 5% stress 
cardiac magnetic resonance imaging. However, the 
stress core laboratories did not confirm whether 
the degree of ischemia was enough to qualify for 
the trial in 13.8% of patients who finally underwent 
randomization. Patients who were determined by 
the core laboratory to have moderate ischemia 
on a non-imaging exercise-stress test did not 
meet ischemia eligibility, yet some such patients 
underwent randomization. Non-imaging exercise 
test criteria were developed to approximate severe 
ischemia, taking into account the potentially higher 
false positive rate. 
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In addition to an evaluation of ischemia, most 
patients underwent computed tomography angio-
graphy (CTA) in order to exclude the presence of 
left main stenosis (≥ 50% stenosis), as well as to 
exclude patients who had less than 50% stenosis 
in all arteries, in whom the presence of significant 
ischemia is less common, and events are generally 
lower [2]. A total of 1266 patients did not undergo 
core-laboratory-interpreted CTA for the trial and 
did not have an available previous CTA within 
1 year before the trial for core-laboratory interpre-
tation, and 923 patients had a CTA core-laboratory 
interpretation in which the number of diseased 
vessels could not be evaluated. When trial images 
could be interpreted for this variable, the number 
of diseased vessels on CTA was based on a 50% 
stenosis threshold. Data on CAD severity based on 
50% stenosis excluded 4 patients with no diseased 
vessels. Stenosis of the proximal left anterior de-
scending coronary artery was reported when the 
proximal left anterior descendant segment could 
be evaluated on CTA. For patients enrolled using 
a non-imaging exercise stress test, anatomic eligi-
bility confirmation was required and CTA eligibility 
criteria were more stringent for them, requiring 
≥ 70% stenosis in the proximal or mid left anterior 
descending, proximal or mid right coronary artery, or 
proximal left circumflex (or circumflex equivalent).
The ISCHEMIA study highlights coronary 
anatomical assessment with cardiac CTA as an 
excellent tool to diagnose and evaluate the sever-
ity of coronary atherosclerosis. The assessment of 
the severity of a stenosis is facilitated using the 
CAD-RADS classification. In the ISCHEMIA study, 
a cardiac CTA scan was recommended, but was not 
required on randomization, which was based on the 
presence of moderate or severe ischemia in func-
tional tests, as previously stated. Besides, cardiac 
CTA by itself did or did not indicate coronary revas-
cularization, which relied on quantitative invasive 
coronary angiography. An optimal quality cardiac 
CTA was attained in more than 50% of patients, of 
which near 99% disclosed at least one major coro-
nary artery with ≥ 50% of luminal stenosis. In this 
regard, the SCOT-HEART study [3] showed that 
a conservative strategy in the treatment of stable 
angina based on cardiac CTA results compared 
with a conservative strategy guided by positive 
functional tests reduces coronary disease mortality 
and the incidence of MI. This benefit, observed af-
ter 5 years of follow-up, was associated with a 60% 
increase in the prescription of antiplatelet therapy 
and high potency statins. Undoubtedly, the effect 
on plaque regression demonstrated with ambitious 
pharmacological therapy underlies the nexus that 
connects these observations.
The results of ISCHEMIA trial should be in-
terpreted with caution and it may not be applicable 
to all patients. A selection bias cannot be excluded, 
and patients with very severe ischemia on the 
stress test might be less likely to be considered for 
study participation. Many patients with left main 
disease were also excluded with coronary CTA, and 
so the results are not applicable to them. 
The question, at this point is: What is the 
role of functional testing and coronary computed 
tomography for patients with stable angina?  Should 
all patients with stable symptoms be treated in 
a conservative manner, and reserve an invasive ap-
proach only if medical therapy alone fails? In light 
of results obtained, it might be wondered whether 
it was necessary for the patients with an evaluation 
for ischemia, if medical therapy would be used to 
treat nearly all stable patients who do not have 
left main disease. However, testing for ischemia 
will continue to have an important role in clinical 
cardiology. Sometimes, in routine clinical practice, 
it is unclear if patient symptoms represent angina 
or not, and an ischemic evaluation can be useful 
in these scenarios. Similarly, older patients or 
with long-standing diabetes frequently have silent 
ischemia, and functional studies could be required 
to identify the optimal diagnostic and therapeutic 
algorithm for them.
One of the strengths of the study is the use-
fulness of the CTA as a first line test to evaluate 
patients with stable symptoms and suspected CAD. 
This trial is another sample of the important role of 
the CTA as gate keeper of the diagnostic workflow, 
as reflected in the recent guidelines [4]. In patients 
who do not have known CAD, coronary CTA has 
an important role in identifying the need for ag-
gressive medical therapy. CTA is also a key that 
can allow ruling out underlying high-risk coronary 
anatomy or left main disease, even though ischemia 
is present, particularly when symptoms are rare 
and conservative management is being considered. 
Indeed, one of the strengths of coronary CTA lies in 
its ability to identify a wide spectrum of CAD, rang-
ing from mild non-obstructive plaque to extensive 
multi-vessel disease. Another advantage of using 
coronary CTA as a front-line test has to do with di-
agnostic efficiency: the majority of individuals with 
no history of CAD who are evaluated with coronary 
CTA will have either no CAD, or non-obstructive 
CAD, and will not need further testing.
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In short, the most relevant conclusion of 
this trial cannot be left in the absence of differ-
ences between the invasive and conservative 
treatment [5]. At this point, one might think if all 
the available technology is being used for identify-
ing which patients could benefit from each therapy 
[6, 7]. The answer to this question is given by the 
coronary CTA and the functional stress test, which 
can stratify risk and guide the algorithm. Trying to 
give an answer without them is to go back to the 
past, and not headed into the future. Going forward 
to the future is the only way to achieve the best 
individualized treatment for each patient. 
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